Smart Innovation
Antimicrobial resistance (AMR)
AMR develops when bacteria, fungi or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, chemotherapy and stem cell therapy may become impossible.
AMR is considered the biggest global threat of Health and Food Safety.
AMR Insights
For Researchers and Entrepreneurs who wish to investigate, develop and commercialize novel vaccines, diagnostics and antimicrobials to prevent Antimicrobial resistance, AMR Insights offers selected, global information and data, specific education and extensive networking and partnering opportunities.
AMR Insights is for:
- Researchers at Universities and University Medical Centers
- Researchers at Research Institutes
- R&D professionals in Pharma, Biopharma and Diagnostics companies
- Entrepreneurs in start-up’s and spin off companies
- Innovators, Venture Capitalists.
Latest Topics
-
28 November 2025Beyond resistance: alternative innovation models for global access and stewardship of new antibiotics
The development of new antibiotics—together with ensuring equitable access and responsible stewardship—is essential to combating AMR. To assess how today’s antibiotic innovation ecosystem supports this goal, researchers reviewed the literature, built a database of 211 antibiotic developers, and interviewed 10 stakeholders. They found that while some companies still follow the traditional market-driven model, most now […]
Read more... -
27 November 2025The Role of Machine Learning in Addressing Antibiotic Resistance: A New Era in Infectious Disease Control
Antimicrobial resistance (AMR) is rising, and traditional methods to address it are slow and expensive, but artificial intelligence (AI) is transforming the field by rapidly analysing vast chemical and biological data to discover new antimicrobial compounds. AI can identify resistance trends, accelerate the development of effective new antibiotics, support faster diagnosis, and help predict emerging […]
Read more... -
21 November 2025GSK and Fleming Initiative scientists unite to target AMR with advanced AI
GlaxoSmithKline (GSK) will invest £45 million in a major new partnership with the Fleming Initiative at Imperial College London to accelerate the fight against antimicrobial resistance (AMR) using advanced artificial intelligence. Beginning in early 2026, both partners will launch six AI-powered “Grand Challenges” that span the full AMR spectrum: discovering new antibiotics and antifungals, predicting […]
Read more...
More news related to Smart innovation
